Qynapse is pleased to participate in the 2020 Alzheimer’s Association International Conference virtual event

Qynapse is thrilled to be part of the Scientific Program of AAIC and the Virtual Exhibition from July 27 to July 31 − to present our latest advances and solutions.

Qynapse receives FDA clearance for QyScore®, a novel imaging software for central nervous system diseases

QyScore® allows automated quantification of a broad portfolio of Magnetic Resonance Imaging markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders

Qynapse releases new validation results of QyScore performance

QyScore®, the software by Qynapse that provides automated volumetric measurements of brain structures, takes a big step forward with the validation of performance for one of its major functionalities

Qynapse partners with AG Mednet

Qynapse is pleased to announce the signing of a partnership agreement with AG Mednet, the leading provider of medical trials data management services, for the use of its Judi imaging adjudication system

Qynapse featured on the French television network “France 3”

On September 20th 2018, Qynapse was featured on the evening news program of the French network France 3 in a report dedicated to Alzheimer’s disease diagnosis

Qynapse part of the “Top 100 start-ups where to invest”

Qynapse was featured in the 2018 selection of the “Top 100 start-ups where to invest”
in the French business magazine Challenges